FARMAC is an electrical contractor in Peer. Private Limited, started on 28 July 2000, 1 establishment.

What is the address of FARMAC?

The registered office of FARMAC is located at Nijverheidsstraat 6, 3990 Peer.

Is FARMAC still active?

Yes. According to the CBE (30 October 2026) FARMAC is active, legal situation “Normale toestand”, started on 28 July 2000.

Is FARMAC registered on Peppol?

Yes, FARMAC is registered on the Peppol network with ID 0208:0472489968.

What is the enterprise number of FARMAC?

The enterprise number of FARMAC is BE0472489968.

When was FARMAC founded?

FARMAC was founded on 28 July 2000.

Who are the directors of FARMAC?

According to the 2025 annual accounts, the directors of FARMAC are: Kirt BV, Metro Solutions BV.

Is FARMAC a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 July 2000; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did FARMAC make in 2025?

FARMAC posted a profit after taxes of € 306,067 in financial year 2025.

What is the revenue of FARMAC?

As a small company, FARMAC is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 4,369,400.

How much does an employee at FARMAC earn?

The average wage cost per full-time employee at FARMAC was € 66,200 in 2025: staff costs of € 3.2 million for 49 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does FARMAC have?

According to the 2025 annual accounts, FARMAC has 49 full-time equivalents (FTE).

FARMAC (Private Limited) - Peer - BE0472489968

Dossier FARMAC, printed on 30 October 2026 from databakkes.be/en/0472489968/farmac. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

FARMAC from Peer, company number BE0472489968, closed financial year 2025 with a result of € 306,067 after tax. For that financial year FARMAC recorded a gross margin of € 4.4 million and equity of € 2.2 million. Compared with financial year 2024, the result moved from € 421,528 to € 306,067. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.

What it is worth Growing

€ 2.2 million

▲ 6% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 306,067

▼ 27% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 127,673

▼ 83% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 180,000 paid out

59 % of the profit went to the shareholders, mostly to MILAX (99 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

▲ 1.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 3.2 million

▲ 18% vs 2024

€ 66,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1.2 million

▲ 27% vs 2024

Of which on lease € 744,941.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 2.2 million

▼ 1% vs 2024

€ 548,124 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 772,684

▲ 39% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 387,658

▲ 26% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 3,463,757 Gross margin 2022: € 3,463,757 First fiscal year in the series	€ 3,599,706 Gross margin 2023: € 3,599,706 ▲ 4% vs 2022 (€ 3,463,757) Favourable step	€ 3,962,825 Gross margin 2024: € 3,962,825 ▲ 10% vs 2023 (€ 3,599,706) Favourable step	€ 4,369,400 Gross margin 2025: € 4,369,400 ▲ 10% vs 2024 (€ 3,962,825) Favourable step	▲ 10%
Profit after taxes	€ 377,073 Profit after taxes 2022: € 377,073 First fiscal year in the series	€ 334,518 Profit after taxes 2023: € 334,518 ▼ 11% vs 2022 (€ 377,073) Unfavourable step	€ 421,528 Profit after taxes 2024: € 421,528 ▲ 26% vs 2023 (€ 334,518) Favourable step	€ 306,067 Profit after taxes 2025: € 306,067 ▼ 27% vs 2024 (€ 421,528) Unfavourable step	▼ 27%
Equity	€ 1,638,890 Equity 2022: € 1,638,890 First fiscal year in the series	€ 1,793,408 Equity 2023: € 1,793,408 ▲ 9% vs 2022 (€ 1,638,890) Favourable step	€ 2,034,936 Equity 2024: € 2,034,936 ▲ 13% vs 2023 (€ 1,793,408) Favourable step	€ 2,161,003 Equity 2025: € 2,161,003 ▲ 6% vs 2024 (€ 2,034,936) Favourable step	▲ 6%
Total debts	€ 2,422,584 Total debts 2022: € 2,422,584 First fiscal year in the series	€ 3,057,318 Total debts 2023: € 3,057,318 ▲ 26% vs 2022 (€ 2,422,584) Unfavourable step	€ 3,260,269 Total debts 2024: € 3,260,269 ▲ 7% vs 2023 (€ 3,057,318) Unfavourable step	€ 3,509,553 Total debts 2025: € 3,509,553 ▲ 8% vs 2024 (€ 3,260,269) Unfavourable step	▲ 8%
Cash	€ 268,917 Cash 2022: € 268,917 First fiscal year in the series	€ 520,706 Cash 2023: € 520,706 ▲ 94% vs 2022 (€ 268,917) Favourable step	€ 751,704 Cash 2024: € 751,704 ▲ 44% vs 2023 (€ 520,706) Favourable step	€ 127,673 Cash 2025: € 127,673 ▼ 83% vs 2024 (€ 751,704) Unfavourable step	▼ 83%
Retained profit	€ 1,620,290 Retained profit 2022: € 1,620,290 First fiscal year in the series	€ 1,774,808 Retained profit 2023: € 1,774,808 ▲ 10% vs 2022 (€ 1,620,290) Favourable step	€ 2,016,336 Retained profit 2024: € 2,016,336 ▲ 14% vs 2023 (€ 1,774,808) Favourable step	€ 2,142,403 Retained profit 2025: € 2,142,403 ▲ 6% vs 2024 (€ 2,016,336) Favourable step	▲ 6%
Dividend	€ 180,000 Dividend 2022: € 180,000 First fiscal year in the series	€ 180,000 Dividend 2023: € 180,000 Unchanged (€ 180,000) Unchanged	€ 180,000 Dividend 2024: € 180,000 Unchanged (€ 180,000) Unchanged	€ 180,000 Dividend 2025: € 180,000 Unchanged (€ 180,000) Unchanged
Bank debt	€ 1,516,860 Bank debt 2022: € 1,516,860 First fiscal year in the series	€ 2,055,708 Bank debt 2023: € 2,055,708 ▲ 36% vs 2022 (€ 1,516,860) Unfavourable step	€ 2,193,655 Bank debt 2024: € 2,193,655 ▲ 7% vs 2023 (€ 2,055,708) Unfavourable step	€ 2,164,436 Bank debt 2025: € 2,164,436 ▼ 1% vs 2024 (€ 2,193,655) Favourable step	▼ 1%
Balance sheet total	€ 4,061,474 Balance sheet total 2022: € 4,061,474 First fiscal year in the series	€ 4,850,726 Balance sheet total 2023: € 4,850,726 ▲ 19% vs 2022 (€ 4,061,474) Unchanged	€ 5,295,205 Balance sheet total 2024: € 5,295,205 ▲ 9% vs 2023 (€ 4,850,726) Unchanged	€ 5,670,556 Balance sheet total 2025: € 5,670,556 ▲ 7% vs 2024 (€ 5,295,205) Unchanged	▲ 7%
Employees (FTE)	45.3 Employees (FTE) 2022: 45.3 First fiscal year in the series	45.3 Employees (FTE) 2023: 45.3 Unchanged (45.3) Unchanged	47.3 Employees (FTE) 2024: 47.3 ▲ 2 vs 2023 (45.3) Unchanged	49 Employees (FTE) 2025: 49 ▲ 1.7 vs 2024 (47.3) Unchanged	▲ 1.7

Key figures of FARMAC, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to FARMAC?

What happened at FARMAC in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 2, 2026 New annual accounts for financial year 2025: profit of € 306,067 (▼ 27% vs 2024). Source: NBB ↗
2025 Kirt BV became a director. NBB
2025 Metro Solutions BV became a director. NBB
Aug 17, 2000 New establishment in Peer. KBO
Jul 28, 2000 Start of the company according to the CBE. KBO

In short

From € 377,073 profit in 2022 to € 306,067 profit in 2025.

Paid € 550,569 in corporate taxes since 2022.

Best year ever: 2024, with € 421,528 profit.

On average € 89,200 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

MILAX 99.5%

The stake of MILAX comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

FARMAC

Behind FARMAC are Kirt BV and Metro Solutions BV. The shares are held by MILAX (99.5%).

Directors

According to the 2025 annual accounts

Kirt BV

Director · represented by Gert Thijs

Also active at: PETERS ELECTRO, MILAX, GETHIJ

since 2025

Metro Solutions BV

Director · represented by Bert Wouters

Also active at: PETERS ELECTRO, BUON VIVERE, MILAX, GETHIJ

since 2025

Shareholders

MILAX

99.5%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Nijverheidsstraat 6

3990 Peer

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.

All companies at this address →

MILAX same network

€ 172,317 gross margin · 2025

GETHIJ same network

€ -4,597 gross margin · 2025

Tijdelijke Maatschap FARMAC-APK

KIRT same network

€ 54,306 gross margin · 2025

BG PARTNERS

+2 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0472.489.968

VAT number

BE 0472.489.968

Registered office

Nijverheidsstraat 6, 3990 Peer

Names & denominations

FARMAC

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

28 July 2000

Peppol

Active · Active since 13 Jan 2025

Activities · NACE

Algemene elektrotechnische installatiewerken

Elektrische installatie

Bouw van civieltechnische werken voor elektriciteit en telecommunicatie

Bouw van water- en gasdistributienetten

View on CBE Public ↗ Annual accounts (NBB) ↗

FARMAC

Financials

What happened to FARMAC?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions